Exscientia, is delighted to note that its Chief Chemist Andy Bell, who previously led a medicinal chemistry team at Imperial College, has published ground-breaking work that identifies novel molecules to treat the common cold.
The research, published in Nature Chemistry, describes work behind the design of IMP-1088, a novel and highly potent anti-viral that prevents the cold virus from making new copies of itself. By targeting a human protein (N-myristoyltransferase) rather than a cold virus protein, the emergence of drug resistance to IMP-1088 is expected to be minimised. Further research leading to human clinical trials is anticipated.
To learn more, see the announcement by Imperial College and the original publication.